A Study of GNTI-122 in Adults Recently Diagnosed With T1D

计划入组 16 人 · 首次发布于 2025 年 4 月 9 日

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

计划入组 271 人 · 首次发布于 2011 年 8 月 23 日

A Rollover Study of CC-122

计划入组 12 人 · 首次发布于 2023 年 1 月 18 日

GNTI-122

GenSci-122

TP-122

JAZZ PHARMACEUTICALS, INC.

United States

Symtrend, Inc.

United States

UNIVERSITY OF CANBERRA

Australia

Regulatory T Cell Therapies Advance Through Clinical Development with Enhanced Monitoring Technologies

Can B Corp Acquires Cannabis Patents Valued at $122 Million Through Court Assignment

Nanjing Leads Biolabs Soars 122% on Hong Kong Debut Following HK$1.1 Billion IPO